| Reference |
|---|
Stojkovic S, Kaun C, Basílio J, Rauscher S, Hell L, Krychtiuk K, et al. Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation. Sci Rep. 2016;6:25171 pubmed publisher |
Däbritz J, Judd L, Chalinor H, Menheniott T, Giraud A. Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells. Sci Rep. 2016;6:20584 pubmed publisher |
Porsbjerg C, Baines K, Gibson P, Bergqvist A, Erjefält J, Sverrild A, et al. IL-33 is related to innate immune activation and sensitization to HDM in mild steroid-free asthma. Clin Exp Allergy. 2016;46:564-74 pubmed publisher |
Reine T, Vuong T, Rutkovskiy A, Meen A, Vaage J, Jenssen T, et al. Serglycin in Quiescent and Proliferating Primary Endothelial Cells. PLoS ONE. 2015;10:e0145584 pubmed publisher |
O Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, et al. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 2016;114:37-43 pubmed publisher |
Chen H, Sun Y, Lai L, Wu H, Xiao Y, Ming B, et al. Interleukin-33 is released in spinal cord and suppresses experimental autoimmune encephalomyelitis in mice. Neuroscience. 2015;308:157-68 pubmed publisher |
Calvén J, Akbarshahi H, Menzel M, Ayata C, Idzko M, Bjermer L, et al. Rhinoviral stimuli, epithelial factors and ATP signalling contribute to bronchial smooth muscle production of IL-33. J Transl Med. 2015;13:281 pubmed publisher |
Lam M, Hull L, Imrie A, Snidvongs K, Chin D, Pratt E, et al. Interleukin-25 and interleukin-33 as mediators of eosinophilic inflammation in chronic rhinosinusitis. Am J Rhinol Allergy. 2015;29:175-81 pubmed publisher |
Millar N, Gilchrist D, Akbar M, Reilly J, Kerr S, Campbell A, et al. MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nat Commun. 2015;6:6774 pubmed publisher |
Malcolm J, Awang R, Oliver Bell J, Butcher J, Campbell L, Adrados Planell A, et al. IL-33 Exacerbates Periodontal Disease through Induction of RANKL. J Dent Res. 2015;94:968-75 pubmed publisher |
Suttle M, Enoksson M, Zoltowska A, Chatterjee M, Nilsson G, Harvima I. Experimentally induced psoriatic lesions associate with rapid but transient decrease in interleukin-33 immunostaining in epidermis. Acta Derm Venereol. 2015;95:536-41 pubmed publisher |
Demyanets S, Kaun C, Pentz R, Krychtiuk K, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16-26 pubmed publisher |
Seltmann J, Werfel T, Wittmann M. Evidence for a regulatory loop between IFN-? and IL-33 in skin inflammation. Exp Dermatol. 2013;22:102-7 pubmed publisher |
Roussel L, Farias R, Rousseau S. IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment. J Allergy Clin Immunol. 2013;131:913-6 pubmed publisher |
Kaieda S, Wang J, Shnayder R, Fishgal N, Hei H, Lee R, et al. Interleukin-33 primes mast cells for activation by IgG immune complexes. PLoS ONE. 2012;7:e47252 pubmed publisher |
Sundlisaeter E, Edelmann R, Hol J, Sponheim J, Küchler A, WEISS M, et al. The alarmin IL-33 is a notch target in quiescent endothelial cells. Am J Pathol. 2012;181:1099-111 pubmed publisher |
Kamekura R, Kojima T, Takano K, Go M, Sawada N, Himi T. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy. 2012;42:218-28 pubmed publisher |
Granne I, Southcombe J, Snider J, Tannetta D, Child T, Redman C, et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS ONE. 2011;6:e24463 pubmed publisher |
Demyanets S, Konya V, Kastl S, Kaun C, Rauscher S, Niessner A, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011;31:2080-9 pubmed publisher |
Küchler A, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen D, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008;173:1229-42 pubmed publisher |
